Alzheimer’s Disease and Mild Cognitive Impairment: Emerging Therapeutic Targets and Treatment Strategies
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 3909
Special Issue Editors
2. Coimbra Institute for Biomedical Imaging and Translational Research, University of Coimbra, Coimbra, Portugal
Interests: pharmacology; Alzheimer’s disease; depression; epilepsy; pharmacokinetics; intranasal administration; nose-to-brain
Special Issues, Collections and Topics in MDPI journals
2. Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain
3. Institute of Neuroscience, University of Barcelona, Barcelona, Spain
Interests: Alzheimer’s disease; APP/PS1; neuroinflammation; dendritic spines; cognitive impairment; high fat diet; metabolic alterations
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Alzheimer’s disease (AD) is the most common type of neurodegenerative disorder, characterized by progressive impairment of memory and other cognitive functions. AD is preceded by mild cognitive impairment (MCI), a transitional state between normal aging and AD, which is an early warning signal of the pathology.
As new disease-modifying treatments become available, accurate prognostics are required to guide treatment and evaluate disease progression in patients with MCI and AD. In this regard, the identification of novel pathological biomarkers is a current cornerstone of scientific investigations. Moreover, drug access to the brain is significantly hampered by the blood–brain barrier and, consequently, drug efficacy may be compromised. In this way, novel stratergies for brain delivery must be exploited in MCI and AD.
The scope of this Special Issue includes the recent advances in therapeutic targets as well as new pharmaceutical formulations and drug delivery systems for the treatment of AD and MCI. We also welcome publications that clarify and update the state-of-art of the mechanisms that underlie both pathologies. Translational investigations from both non-clinical and clinical approaches would be of great significance.
Dr. Ana Fortuna
Dr. Miren Ettcheto Arriola
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer’s disease
- mild cognitive impairment
- pharmacokinetics
- pharmacodynamics
- drug formulations
- brain delivery
- dendritic spines
